Verdiva Bio Joins Society for Clinical Research Sites (SCRS) as a Global Impact Partner
February 19, 2025 – The Society for Clinical Research Sites (SCRS) announced today that Verdiva Bio, a clinical-stage biotechnology company focused on developing innovative therapies for obesity and other cardiometabolic disorders, has joined the SCRS Global Impact Partner (GIP) program. As the first biotechnology company to join the program, Verdiva Bio will bring a unique perspective to the group of more than 70 research sites, CROs, and pharmaceutical sponsors.
Verdiva Bio’s pipeline includes a potential first-in-class once weekly oral amylin agonist, a potential best-in-class subcutaneous amylin agonist, and a Phase 2 ready, potential first-in-class, once weekly oral GLP-1 receptor agonist, along with other undisclosed programs. Verdiva plans to advance the development of these next-generation therapeutic candidates via a mix of monotherapy and combination programs with the goal of providing more patient-friendly therapeutic options to people living with obesity, cardiometabolic disorders, and related complications.
“We are proud to be a SCRS Global Impact Partner, where we have the opportunity to deepen our understanding of the needs of clinical trial sites and aim to deliver patient-centric solutions for clinical research. We look forward to working closely with our site partners and understanding what they need for success, so we can aim to optimize trial processes to accelerate the development of our product candidates,” said Chris Clevenger, SVP Clinical Operations & Medical Affairs at Verdiva Bio.
“SCRS is thrilled to welcome Verdiva Bio as the first biotechnology company to join the SCRS Global Impact Partner program,” said Marcus Maleck, Vice President of Global Business Partnerships at SCRS. “Their expertise in obesity and cardiometabolic research brings a valuable perspective to our community of sites, CROs, sponsors and service providers. We look forward to collaborating on solutions that support research site success and industry partnerships.”
As a GIP, Verdiva Bio will contribute to SCRS initiatives, working groups, and advisory boards, gaining valuable insights into site operations while sharing expertise in patient recruitment, budgeting, and operational strategy. The partnership provides Verdiva Bio with direct engagement opportunities across SCRS’s global network of research sites, allowing for collaboration on critical site challenges and trial efficiencies. Learn more about SCRS Global Impact Partners at myscrs.org/industry-partnerships/global-impact-partners.
About Verdiva Bio
Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Verdiva’s most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated potential for best-in-class efficacy and once-weekly dosing in a phase 1 study in Australia. The Company is also developing a portfolio of amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs that, if successful, may offer the potential for enhanced efficacy, improved tolerability, and healthier weight loss. The Verdiva team harnesses the emerging science in gut-brain biology and leverages their history of successful drug development to advance novel therapeutic candidates aiming to transform the lives of millions living with obesity worldwide. For more information, please visit www.verdivabio.com.
About the Society for Clinical Research Sites (SCRS)
The Society for Clinical Research Sites (SCRS) is the leading advocacy organization dedicated to unifying the voice of the global clinical research site community. Representing more than 11,000 research sites in 50+ countries, SCRS facilitates industry collaborations and conversations dedicated to site-focused advocacy, education, mentorship, and connection. SCRS is an active and influential champion for sites in industry initiatives to ensure that the perspective of sites is heard and valued. Learn more and get involved at myscrs.org. Our voice. Our community. Your success.
